Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Licenses Gene Targeting Technology to AstraZeneca

NEW YORK, Dec. 22 (GenomeWeb News) - Lexicon Genetics has non-exclusively licensed to AstraZeneca the rights to its gene-targeting technologies for use in drug discovery research, the company said today.


The Woodlands, Texas company did not disclose the financial terms of the license which revolves around the company's patented technology for discovering gene function in vivo using knockout mice.


Aventis, Pfizer, GlaxoSmithKline, Merck, and Millennium Pharmaceuticals are among the other licensees of Lexicon's technology


This licensing deal comes on the heels of a $66 million drug discovery collaboration with Bristol-Myers Squibb, which the company announced last Friday.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.